Podcast profile
By STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Latest episode
28 min
Topics
Healthcare software, virtual care, health platforms, patient experience, and digital services.
Biological research, therapeutics, diagnostics, genomics, and biotechnology companies.
Startup financing, venture investing, fundraising, portfolio strategy, and private markets.
Formats
Host-led conversation where a guest supplies most of the subject matter.
Interpretation, opinion, debate, review, and analytical discussion.
Audience level
Assumes basic technology literacy and familiarity with common products, roles, and terminology.
Stay connected
From the feed
Episodes shown — 10 of 25
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this week's episode of "The Readout LOUD."
On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward?
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech.
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast.
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast.
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America.
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center).
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches?